METHOD FOR PREVENTION OF RECURRENT ATRIAL FIBRILLATION FOLLOWING CARDIOSURGICAL OPERATIONS Russian patent published in 2015 - IPC A61B17/02 A61B18/12 A61N1/06 A61K31/343 A61P9/06 A61B5/02 A61B5/402 

FIELD: medicine.

SUBSTANCE: preoperative stage involves using amiodarone 0.6-1.2 g/day with ECG and heart rate monitoring to achieve a total dose of 9.6-10.2 g. If QT interval is no more than 500 msec with the absence of cardiac conduction disease and bradycardia events, a maximum dose of the preparation is administered. If observing cardiac conduction disease and bradycardia events following an initial daily dose, a dosage is supposed to decrease daily by 0.2 g/day, but not less than 0.6 g/day to achieve normal ECG. A principal stage of the operation is combined with radiofrequency ablation of pulmonary venous entries and auricles. Besides, two electrodes are intraoperatively anchored to a right auricle and a right ventricle and attached to an external pacemaker. Starting from the intraoperative period and further, a bipolar dual electric cardiac stimulation is performed with a heart rate 10 beats/min as much as a proper rhythm with proper rhythm monitoring for 7-10 days. After the operation, intravenous amiodarone administration continues in a dose of 0.4 g/day on the operative day, in a dose of 0.2-0.4 g/day on the second postoperative day. Further, amiodarone is administered in the tabletted form orally in a dose of 0.2 g/day for 6 months with ECG monitoring. The preparation is withdrawn with persistent sinus rhythm and the absence of paroxysmal events of atrial fibrillation.

EFFECT: more effective prevention of recurrent atrial fibrillation by optimising the combination anti-arrhythmic medication and electric stimulation therapy.

2 ex